{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T07:03:00Z","timestamp":1780815780243,"version":"3.54.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The prevalence of glucocorticoids (GCs) administration in pediatric populations has resulted in numerous adverse reactions, notably osteoporosis. Given its role in managing glucocorticoid-induced osteoporosis, the efficacy and safety of bisphosphonates hold considerable importance. This study conducted a meta-analysis by systematically reviewing and incorporating relevant literature on the efficacy and safety of bisphosphonates in the management of osteoporosis or bone infarction induced by GCs therapy in pediatric populations. Additionally, the analysis of potential adverse reactions was augmented by utilizing real-world data from the FAERS database. The primary objective of this study is to offer insights and guidance for the treatment of glucocorticoid induced osteoporosis in pediatric patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A meta-analysis was performed on existing literature to assess the efficacy and safety of bisphosphonates for managing glucocorticoid-induced osteoporosis. Additionally, a retrospective pharmacovigilances study was carried out to investigate adverse reactions and medication variations in pediatric patients with glucocorticoid-induced osteoporosis, using data from the FDA Adverse Event Reporting System (FAERS) database between Q1 2004 and Q4 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The meta-analysis incorporated a total of 14 articles encompassing 572 patients. The findings of this study indicate that bisphosphonate therapy is more effective in enhancing bone mineral density (BMD) and BMD <jats:italic>Z<\/jats:italic>-scores in children compared to the control group, albeit with a heightened risk of adverse reactions. Furthermore, there was no significant disparity observed between the impact of bisphosphonate treatment and control groups on fracture outcomes. Subsequently, in the ensuing Pharmacovigilance investigation, 668 instances of adverse reactions associated with bisphosphonates are analyzed. The findings indicated that the most prevalent adverse reactions, as evidenced by the highest number of positive signals were various examinations, musculoskeletal and connective tissue diseases, injuries, poisoning and operational complications, as well as systemic diseases and reactions at the administration site.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study conducted a comprehensive analysis of the efficacy and safety of bisphosphonates in the treatment of osteoporosis caused by GCs use in pediatric patients, laying the groundwork for future research. Nevertheless, the constraints of retrospective studies highlight the need for additional investigation through prospective studies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1571381","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T05:28:09Z","timestamp":1751866089000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of bisphosphonates in pediatric glucocorticoid-induced osteoporosis: a meta-analysis and pharmacovigilance study"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaolin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luquan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huawei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00431-022-04743-x","article-title":"Osteoporosis in children and adolescents: how to treat and monitor?","volume":"182","author":"Ciancia","year":"2023","journal-title":"Eur J Pediatr"},{"key":"B2","doi-asserted-by":"publisher","first-page":"101793","DOI":"10.1016\/j.berh.2022.101793","article-title":"Risk for osteoporosis and fracture with glucocorticoids","volume":"36","author":"Urquiaga","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.semarthrit.2014.02.002","article-title":"A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children","volume":"44","author":"Hansen","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"B4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1590\/1984-0462;2017\/;35;2;00007","article-title":"Glucocorticoid-induced bone disease: mechanisms and importance in pediatric practice. Doen\u00e7a \u00f3ssea induzida pelos glicocorticoides: mecanismos e import\u00e2ncia na pr\u00e1tica pedi\u00e1trica","volume":"35","author":"Sarinho","year":"2017","journal-title":"Rev Paul Pediatr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1590\/1984-0462\/;2019;37;1;00001","article-title":"Is there an association between glucocorticoid use and fractures? A comparative study in a trauma hospital. Existe associa\u00e7\u00e3o entre o uso de glicocorticoides e a presen\u00e7a de fraturas? Estudo comparativo em um hospital de trauma","volume":"37","author":"Melo","year":"2019","journal-title":"Rev Paul Pediatr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s00467-014-2834-3","article-title":"Bone health in children and adolescents with steroid-sensitive nephrotic syndrome assessed by DXA and QUS","volume":"29","author":"Aceto","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"108168","DOI":"10.1016\/j.pharmthera.2022.108168","article-title":"Advances in pathogenesis and therapeutic strategies for osteoporosis","volume":"237","author":"Song","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"908727","DOI":"10.3389\/fendo.2022.908727","article-title":"Prevention and treatment of glucocorticoid-induced osteoporosis in adults: consensus recommendations from the Belgian bone club","volume":"13","author":"Laurent","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","article-title":"Drug therapy for osteoporosis in older adults","volume":"399","author":"Reid","year":"2022","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e220334","DOI":"10.20945\/2359-4292-2022-0334","article-title":"Long-term consequences of osteoporosis therapy with bisphosphonates","volume":"68","author":"Gehrke","year":"2023","journal-title":"Arch Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11926-003-0085-6","article-title":"Bisphosphonate mechanism of action","volume":"5","author":"Reszka","year":"2003","journal-title":"Curr Rheumatol Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1124\/mi.10.3.5","article-title":"Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition","volume":"10","author":"Drake","year":"2010","journal-title":"Mol Interv"},{"key":"B14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7326\/M19-0533","article-title":"Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review","volume":"171","author":"Fink","year":"2019","journal-title":"Ann Intern Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.4045\/tidsskr.09.0470","article-title":"Bisfosfonatbehandling av osteoporose og andre skjelettsykdommer. [Bisphosphonate treatment of osteoporosis and other skeletal diseases]","volume":"131","author":"Syversen","year":"2011","journal-title":"Tidsskr Nor Laegeforen"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1111\/bcp.14780","article-title":"Bisphosphonate nephropathy: a case series and review of the literature","volume":"87","author":"de Roij van Zuijdewijn","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1345\/aph.1H521","article-title":"Bisphosphonate-induced osteonecrosis of the jaw","volume":"41","author":"Krueger","year":"2007","journal-title":"Ann Pharmacother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/rheumatology\/keh538","article-title":"Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment","volume":"44","author":"Rudge","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"c81","DOI":"10.1159\/000089664","article-title":"Pamidronate therapy for preventing steroid-induced osteoporosis in children with nephropathy","volume":"102","author":"Kim","year":"2006","journal-title":"Nephron Clin Pract"},{"key":"B20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.eclinm.2019.06.004","article-title":"The prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: a randomised double-blind controlled trial","volume":"12","author":"Rooney","year":"2019","journal-title":"EClinicalMedicine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1210\/clinem\/dgab302","article-title":"Randomized controlled trial evaluating the use of zoledronic acid in Duchenne muscular dystrophy","volume":"106","author":"Zacharin","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e5222","DOI":"10.1210\/clinem\/dgab458","article-title":"Zoledronic acid vs placebo in pediatric glucocorticoid-induced osteoporosis: a randomized, double-blind, phase 3 trial","volume":"106","author":"Ward","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s00467-004-1790-8","article-title":"Pamidronate treatment of pediatric fracture patients on chronic steroid therapy","volume":"20","author":"Acott","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1440-1754.2005.00720.x","article-title":"Attempted randomized controlled trial of pamidronate versus calcium and calcitriol supplements for management of steroid-induced osteoporosis in children and adolescents","volume":"41","author":"Brown","year":"2005","journal-title":"J Paediatr Child Health"},{"key":"B25","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s10067-008-0864-6","article-title":"Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases","volume":"27","author":"Inoue","year":"2008","journal-title":"Clin Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12969-018-0258-5","article-title":"Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study","volume":"16","author":"Inoue","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1159\/000512730","article-title":"Outcomes of zoledronic acid use in paediatric conditions","volume":"93","author":"Lim","year":"2020","journal-title":"Horm Res Paediatr"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1007\/s12325-022-02179-1","article-title":"Effectiveness of neridronate in the management of bone loss in patients with Duchenne muscular dystrophy: results from a pilot study","volume":"39","author":"Moretti","year":"2022","journal-title":"Adv Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/mus.27416","article-title":"The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid-induced osteoporosis","volume":"64","author":"Nasomyont","year":"2021","journal-title":"Muscle Nerve"},{"key":"B30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/mus.24991","article-title":"Prophylactic oral bisphosphonate therapy in Duchenne muscular dystrophy","volume":"54","author":"Srinivasan","year":"2016","journal-title":"Muscle Nerve"},{"key":"B31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.nmd.2020.06.005","article-title":"Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy","volume":"30","author":"Tian","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"B32","doi-asserted-by":"publisher","first-page":"100756","DOI":"10.1016\/j.bonr.2021.100756","article-title":"Spontaneous bone infarction of the distal femur in a patient with Cushing\u2019s disease: a case report","volume":"14","author":"van Houten","year":"2021","journal-title":"Bone Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1007\/s00198-022-06455-2","article-title":"Sickle cell bone disease and response to intravenous bisphosphonates in children","volume":"33","author":"Grimbly","year":"2022","journal-title":"Osteoporos Int"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e016788","DOI":"10.1136\/bmjopen-2017-016788","article-title":"Oral glucocorticoid use and osteonecrosis in children and adults with chronic inflammatory diseases: a population-based cohort study","volume":"7","author":"Horton","year":"2017","journal-title":"BMJ Open"},{"key":"B35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12969-020-0411-9","article-title":"Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children","volume":"18","author":"Galindo-Zavala","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3389\/fendo.2020.00576","article-title":"Glucocorticoid-induced osteoporosis: why kids are different","volume":"11","author":"Ward","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11914-019-00498-x","article-title":"Glucocorticoid-Induced osteoporosis: new insights into the pathophysiology and treatments","volume":"17","author":"Lane","year":"2019","journal-title":"Curr Osteoporos Rep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"67","author":"Wallach","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e80890","DOI":"10.1371\/journal.pone.0080890","article-title":"Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systematic review and meta-analysis","volume":"8","author":"Feng","year":"2013","journal-title":"PLoS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"CD001347","DOI":"10.1002\/14651858.CD001347","article-title":"Bisphosphonates for steroid induced osteoporosis","author":"Homik","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"B42","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00198-004-1614-5","article-title":"Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies","volume":"15","author":"de Nijs","year":"2004","journal-title":"Osteoporos Int"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00198-023-06863-y","article-title":"Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study","volume":"34","author":"Everts-Graber","year":"2023","journal-title":"Osteoporos Int"},{"key":"B44","doi-asserted-by":"publisher","first-page":"CD001347","DOI":"10.1002\/14651858.CD001347.pub2","article-title":"Bisphosphonates for steroid-induced osteoporosis","volume":"10","author":"Allen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B45","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1136\/jim-2021-001961","article-title":"Effect of bisphosphonate on hip fracture in patients with osteoporosis or osteopenia according to age: a meta-analysis and systematic review","volume":"70","author":"Zhao","year":"2022","journal-title":"J Investig Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00223-011-9499-8","article-title":"Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis","volume":"89","author":"Rizzoli","year":"2011","journal-title":"Calcif Tissue Int"},{"key":"B47","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2106\/JBJS.K.01181","article-title":"Bisphosphonates and nonhealing femoral fractures: analysis of the FDA adverse event reporting system (FAERS) and international safety efforts: a systematic review from the research on adverse drug events and reports (RADAR) project","volume":"95","author":"Edwards","year":"2013","journal-title":"J Bone Joint Surg Am"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of all atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1359\/jbmr.080511","article-title":"Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases","volume":"23","author":"Whyte","year":"2008","journal-title":"J Bone Miner Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"96","DOI":"10.14310\/horm.2002.1226","article-title":"Bisphosphonate-associated adverse events","volume":"8","author":"Papapetrou","year":"2009","journal-title":"Hormones (Athens)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/ger.12590","article-title":"Oral bisphosphonates: adverse effects on the oral mucosa not related to the jaw bones. A scoping review","volume":"39","author":"Psimma","year":"2022","journal-title":"Gerodontology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e14340","DOI":"10.1097\/MD.0000000000014340","article-title":"A prospective comparative study of intravenous alendronate and ibandronate for the treatment of osteoporosis","volume":"98","author":"Horikawa","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1571381\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T05:28:10Z","timestamp":1751866090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1571381\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":53,"alternative-id":["10.3389\/fped.2025.1571381"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1571381","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"article-number":"1571381"}}